CAS Investment Management has returned for a $34m series A-plus round that was led by CDH Wealth Management.

China-based drug discovery platform Zonsen Peplib Biotech has secured RMB220 ($34m) in a series A-plus round backed by CAS Investment Management, an investment firm co-founded by Chinese Academy of Sciences, according to DealStreetAsia.
CDH Wealth Management, a unit of alternative asset manager CDH Investments, led the round, which also included conglomerate Legend Holdings’ early-stage investment arm Legend Star.
ASB Ventures, Highlight Capital, Cowin Capital and Fortune Capital filled out the round.
Founded in 2017, Zonsen has developed technology to manufacture individual peptide compounds or peptide libraries in a cost and time-efficient way. It will use the funding to further develop its platform, progress its pipeline and hire more staff.
The company raised $14m in a series A round in July 2019, and DealStreetAsia identified CAS Investment Management as a returning backer for the latest transaction.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.